Risnia
In brief
- In our pharmacy, Risnia (risperidone) can be purchased without a prescription, with delivery across the United Kingdom in 9–21 days and discreet, anonymous packaging. Risperidone is a prescription-only medicine in the UK.
- Risperidone is used to treat schizophrenia and bipolar mania; it is an atypical antipsychotic that works mainly by antagonising dopamine D2 and serotonin 5‑HT2A receptors.
- The usual dose for adults with schizophrenia is to start at 2 mg/day with a target of 4–6 mg/day (maximum 16 mg/day, split doses); for bipolar mania the typical starting dose is 2 mg once daily (usually up to 6 mg/day); paediatric and elderly doses are lower and require careful titration.
- Administered orally as tablets (0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg), orally disintegrating tablets (0.5–4 mg) or as an oral solution (1 mg/mL).
- Onset: calming or sedative effects may be seen within hours; noticeable antipsychotic improvements often begin within days to 1–2 weeks, with fuller clinical benefit typically developing over 4–6 weeks.
- Duration of action: oral risperidone generally provides coverage for about 24 hours per dose and is taken daily for ongoing effect; clinical maintenance is measured in weeks to months.
- Alcohol warning: avoid alcohol while taking risperidone — alcohol can increase sedation, impair coordination, worsen orthostatic hypotension and raise the risk of adverse effects.
- The most common side effect is drowsiness/fatigue (other frequent effects include insomnia, weight gain, dizziness, nausea, constipation and extrapyramidal symptoms such as tremor or stiffness).
- Would you like to try Risnia without a prescription?
Basic Risnia information
- INN (international nonproprietary name): Risperidone.
- Brand names available in the United Kingdom: Risperdal (originator) and generic risperidone (for example Teva, Mylan, Sandoz); Risnia is a risperidone brand that is not licensed in the UK.
- ATC code: N05AX08.
- Forms and dosages: tablets 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg; orodispersible tablets; oral solution 1 mg/mL.
- Manufacturers in the United Kingdom: Janssen‑Cilag (Risperdal); generics from Teva, Mylan and Sandoz.
- Registration status in the United Kingdom: risperidone (Risperdal and generics) is MHRA-licensed; Risnia is not licensed in the UK.
- OTC / Rx classification: Prescription-only medicine (POM).
Names and formulations
The active substance is risperidone (ATC code N05AX08). In the UK the originator brand is Risperdal; generic risperidone is also available. Risnia is a risperidone brand that is not licensed in the UK.
Dosage forms and strengths
Risperidone is available as tablets, orodispersible tablets (ODT/M‑Tab) and oral solution (1 mg/mL).
Indications and approved uses
Adult indications
Risperidone is approved for schizophrenia and for acute mania in bipolar disorder in adults.
Typical starting guidance for schizophrenia is 2 mg per day (once daily or in two divided doses), increased to 4 mg on the second day, with a usual target of 4–6 mg per day depending on response.
For bipolar mania a common starting dose is 2 mg once daily with adjustment in steps of 1–2 mg, usually within 1–6 mg per day.
Children and adolescents
In the UK risperidone is licensed in children from 5 years of age only for short-term treatment of persistent aggression in conduct disorder; use for schizophrenia or bipolar mania is not recommended under 18 years. Dosing in children starts lower and is titrated carefully according to age and tolerability.
Maintenance durations vary and require regular specialist or GP review.
Dosing, titration and special populations
Titration principles
Start low and increase gradually based on clinical response and tolerability.
Split doses may be used for tolerability in schizophrenia, while once‑daily dosing is common for bipolar mania.
Missed dose: take when remembered unless it is close to the next dose; do not double up.
Children, elderly and organ impairment adjustments
Children require reduced initial dosing and slow titration, reflecting licensed age limits and higher sensitivity to side effects.
Elderly patients should typically start at 0.5 mg twice daily and be titrated carefully because of increased sensitivity.
Patients with liver or kidney impairment should start at lower doses and be up‑titrated cautiously with monitoring.
Overdose signs include drowsiness, hypotension, tachycardia and extrapyramidal symptoms — seek urgent medical attention if these occur.
Contraindications and cautions
Absolute contraindications
Absolute contraindications include known hypersensitivity to risperidone or any product component.
Dementia‑related psychosis in elderly patients is not an approved indication and has an associated increased mortality risk.
ODT/M‑Tab products may contain aspartame and should be avoided by people with phenylketonuria.
Relative risks
Cautions apply for cardiovascular disease due to QT prolongation risk, for epilepsy, for Parkinson’s disease and for diabetes because of hyperglycaemia risk.
In renal or hepatic impairment a lower starting dose and monitoring are appropriate.
Report any new or worsening symptoms to the GP or specialist for review.
Side effects, metabolic risks and monitoring
Common adverse effects
Common effects include insomnia, headache, drowsiness, increased appetite and weight gain, dizziness, nausea or constipation and anxiety or restlessness.
Movement‑related adverse events such as tremor or stiffness (extrapyramidal symptoms) are more likely at higher doses and must be reported promptly.
Recommended monitoring schedule
Monitoring is usually arranged through the GP or clinic before starting and during follow‑up.
| Parameter | Baseline | Follow‑up |
|---|---|---|
| Weight / BMI | Measure before start | 3 months, then at least annually |
| Fasting glucose / HbA1c | Baseline sample | 3 months, then annually (or sooner if symptomatic) |
| Lipids | Baseline fasting lipids | 3 months, then annually |
| Blood pressure / pulse | Baseline reading | Regular checks during dose changes |
| Movement disorder screening | Baseline assessment | At each review and if new symptoms |
Report promptly any signs of neuroleptic malignant syndrome (high fever, rigidity) or tardive dyskinesia (involuntary movements).
Drug interactions and prescribing cautions
Interacting drug classes
Drugs that prolong the QT interval should be checked because of additive risk.
CNS depressants increase sedation when used with risperidone.
Potent CYP2D6 inhibitors can raise risperidone levels and require prescriber awareness.
Concomitant use with other dopamine antagonists, including metoclopramide, increases the risk of extrapyramidal symptoms.
Managing common interactions
A clinically important interaction should be discussed with the prescriber.
Watch for palpitations, fainting, excessive sedation or new movement problems and seek urgent review if these occur.
| Interaction | Risk | Action |
|---|---|---|
| QT‑prolonging agents | Arrhythmia risk | Check ECG history; query prescriber |
| CNS depressants (opioids, benzodiazepines) | Increased sedation | Counsel on avoidance of driving; monitor |
| CYP2D6 inhibitors | Increased risperidone exposure | Alert prescriber to consider dose adjustment |
| Dopamine antagonists (metoclopramide) | Higher EPS risk | Advise prescriber; monitor for tremor/stiffness |
Alternatives and when to choose risperidone
Key alternatives
Common comparators are olanzapine, quetiapine, aripiprazole, haloperidol and paliperidone.
These drugs differ in metabolic risk (olanzapine is typically higher), extrapyramidal risk (higher with typicals such as haloperidol).
Patient‑centred choice points
Risperidone is a reasonable option where a balance of efficacy and tolerability is sought and where oral solution or ODT formulations aid adherence.
Switching between antipsychotics requires prescriber‑led cross‑titration and monitoring for withdrawal or rebound symptoms.
| Drug | Metabolic risk | EPS risk |
|---|---|---|
| Risperidone | Moderate | Moderate |
| Olanzapine | High | Low–Moderate |
| Quetiapine | Moderate–High | Low |
| Aripiprazole | Low | Low |
| Haloperidol | Low | High |
Legal status and availability in the UK
In our online pharmacy, Risnia is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Risperidone is a prescription-only medicine (POM) in the UK. Risnia is not licensed in the UK.
Storage and handling
Storage conditions
Store risperidone at 20–25°C and protect from excessive moisture and heat.
Handling oral solution and ODTs
Oral solution should be used within three months of opening unless the local pack states otherwise.
ODT/M‑Tab dispersible products may contain aspartame and should carry a PKU warning for patients with phenylketonuria.
| Formulation | Storage | After‑opening lifespan |
|---|---|---|
| Tablets | 20–25°C, dry | Until expiry |
| Oral solution (1 mg/mL) | 20–25°C, protect from heat | Use within 3 months of opening (check pack) |
| ODT / M‑Tab | 20–25°C, dry | Until expiry; note PKU warning |
For disposal, advise patients to return unused medicines to a pharmacy medicine take‑back service.
Counselling points
Key points to remember
- Check that the medication is risperidone and that the dosing schedule matches your prescription.
- It may cause sedation; take care when driving or operating machinery until you know how it affects you.
- Common side effects include drowsiness, insomnia, headache, increased appetite and movement symptoms.
- Weight and metabolic monitoring is advised through your GP or clinic.
- People using ODTs should note the PKU/aspartame content if relevant.
- Missed dose: take it if remembered, skip it if close to the next dose; seek urgent care for signs of overdose.
Switching and adherence aids
Switching guidance and depot options
Switching between antipsychotics requires prescriber involvement with a planned cross‑titration and monitoring for withdrawal or rebound symptoms.
Consider long‑acting injectable alternatives where adherence is a concern and discuss depot options with the prescriber and patient.
Adherence tools
Adherence aids such as blister packs, reminder apps, supervised dosing or repeat dispensing services can help.
| Adherence aid | Benefit |
|---|---|
| Blister packs | Improves dosing accuracy and visual reminders |
| Reminder apps | Supports daily dosing and refill reminders |
| Repeat dispensing | Reduces prescription‑renewal friction |
Early follow‑up at 1–2 weeks helps address tolerability and improve long‑term adherence.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | South West | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Newcastle | Tyne and Wear | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Leicester | Leicestershire | 9–21 days |
| Coventry | West Midlands | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
Final notes
Confirm the active ingredient shown as risperidone and check the formulation and strength against the prescription.
Ask about likely side effects such as drowsiness and weight gain, and about metabolic monitoring before long‑term use.
If switching antipsychotics or considering depot options, ensure a prescriber‑led plan and prompt follow‑up to monitor response and tolerability.
